TrialNature medicine2023

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.

Yan Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.